Bladder
After a response to EV+pembro, the next step is an open RT question: bladder-preserving RT, RC or surveillance, with no head-to-head data.
AUA 2026: Consolidative local therapy after EV+pembro response (surgery vs radiation vs surveillance)
TL;DRRT-based preservation, cystectomy and surveillance each argued for cCR after neoadjuvant EV+pembro in MIBC; no randomized data compare the three options.
Reported via UroToday →
This point-counterpoint session asked how to manage the bladder in MIBC after cCR on neoadjuvant EV+pembro. The RT case held that clinical restaging misses residual disease, and that RT-based preservation keeps the bladder with better sexual function and body image than cystectomy. The surgical case held that all level 1 EV+pembro data include cystectomy, and that cCR predicts pCR only 51% of the time. The surveillance case shifted the question from pCR to MFS. It rested on a 97% PPV of cCR for 2-year MFS and on local recurrence coming before metastasis, which would allow salvage. ctDNA was presented as promising but not yet able to select pts.
- No data were shown on RT consolidation after EV+pembro; the RT case rests on chemo-era cohorts and observational TMT vs RC QOL comparisons, where pts chose their modality.
- The 97% PPV comes from GC + nivo in HCRN GU16-257; applying it to EV+pembro assumes a cCR means the same thing under a different regimen.
- The 51% cCR-pCR concordance measures residual pathology, not whether that residual changes MFS once surveillance and salvage are in place, so the surgical case treats pCR as if it were an outcome.
- RETAIN-1 vs RETAIN-2 is a cross-trial comparison in small surveillance cohorts (N=22 in RETAIN-2) after AMVAC-based therapy, not EV+pembro, and no trial compares RT, cystectomy and surveillance head to head.
KEYNOTE-905/EV-303KEYNOTE-B15/EV-304SWOG 0219RETAIN-1RETAIN-2HCRN GU16-257ARCHERBRIGHT
For RT, the key observation is the failure pattern: in RETAIN-2, no pt developed mets without a prior local recurrence, which is the premise behind both salvage RT and surveillance. BRIGHT (55 Gy/20 fx whole bladder, then pembro) is the trial that will test whether RT consolidation after cT0–T1 response adds bladder control beyond surveillance. No EV-era RT data exist yet.
In MIBC with cCR after neoadjuvant EV+pembro, the evidence leaves cystectomy, RT-based preservation and surveillance all open, each supported only by non-randomized or chemo-era data. It does not apply to pts with residual MIBC on restaging TURBT. The longer read
No EV-era data support RT consolidation after cCR yet. BRIGHT (55 Gy/20 fx whole bladder, then pembro for 12 mo) is the test. The local-before-metastatic failure pattern in RETAIN is what makes salvage RT a credible backstop for pts on surveillance.
Both phase III EV+pembro trials mandated cystectomy, and pooled cCR-pCR concordance is 51%, so omitting RC means leaving level 1 evidence behind. ctDNA negativity does not rule out ≥pT2 disease (67% residual), so a negative test cannot yet justify skipping surgery.
11 details 4 trials watching
AUA 2026 point-counterpoint session with three advocates (RT, cystectomy, surveillance), reported in a UroToday write-up. It argues across published and presented data and reports no new trial result.
MIBC (cT2–T4aN0M0 in the cited trials) with clinical complete response after neoadjuvant EV+pembro, i.e. the population treated per KEYNOTE-905/EV-303 and KEYNOTE-B15/EV-304.
The slide shows the BRIGHT schema: RT 55 Gy/20 fx to the whole bladder, then pembro 200 mg q21 days for 12 months, in pts with a cT0–T1 response confirmed by TURBT with systematic biopsies after ≥3 cycles of NAT. The ARCHER arm regimens were not legible on the slide.
In EV-303 and EV-304, every pt was planned for cystectomy, so the EFS and OS benefits (EV-303 EFS HR 0.40, OS HR 0.50) reflect EV+pembro plus RC. Organ-sparing evidence comes from RETAIN-1/2 and HCRN GU16-257, which used chemo or chemo-IO backbones, not EV+pembro.
The disagreement comes down to which endpoint cCR has to predict. Against pCR, cCR fails often (51% concordance); against MFS, it looked accurate in one GC + nivo trial (PPV 97%). If local failure reliably comes before metastasis, salvage keeps that miss from costing a cure, but this has not been shown after EV+pembro.
The trial IDs for ARCHER and BRIGHT differ between the write-up and the slide. The QOL comparison mixes TMT cohorts where pts chose their modality, and it shows worse pain and emotional functioning with TMT.
| Option | Core argument | Evidence cited |
|---|---|---|
| Bladder-preserving RT | cCR does not guarantee eradication; RT gives durable bladder control with a QOL advantage | SWOG 0219, RETAIN-2, TMT vs RC patient-reported outcomes |
| Radical cystectomy | Cystectomy is the backbone of all level 1 EV+pembro data; cCR is not pCR | KEYNOTE-905/EV-303, KEYNOTE-B15/EV-304, Roessler meta-analysis, RETAIN ctDNA |
| Surveillance | Most pts had pCR at cystectomy anyway; the real question is whether cCR predicts MFS | HCRN GU16-257, RETAIN failure patterns, ctDNA (Epstein, ASCO GU 2026) |
| Outcome | RETAIN-1 | RETAIN-2 |
|---|---|---|
| Local recurrence | 62% | 36% |
| Metastatic recurrence | 36% | 14% |
| MFS with intact non-irradiated bladder | 48% | 68% |
- Does cCR after EV+pembro predict MFS as it did after GC + nivo? not yet A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer Phase 2n=25 · primary completion 2034-11 · EV+P clinical response-based sparing, no RC or RT
- Does RT consolidation improve bladder control over surveillance after cCR? recruiting Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) Phase 3n=390 · primary completion 2030-03 · phase 3 EV+P alone vs chemoRT for bladder preservationn=56 · primary completion 2031-04 · response-adapted EV+P induction, then RT, CRT or RC
- Can ctDNA select pts to safely omit cystectomy? recruiting NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment Phase 2/3n=688 · primary completion 2028-12 · ctDNA/MRI-selected surveillance vs definitive therapy